Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Rueda JR et al. – Currently there is no robust evidence to support recommendations on pharmacological treatments in patients with FXS in general or in those with an additional diagnosis of ADHD or autism.

Related Articles

FUS-Immunoreactive Intranuclear Inclusions in Neurodegenerative Disease
Brain Pathology, 10/16/09    Relevance Score: 78%

Characterization of a new X-linked mental retardation syndrome with microcephaly, cortical malformation, and thin habitus
American Journal of Medical Genetics, 10/23/09    Relevance Score: 67%

Munchausen syndrome in the emergency department mostly difficult, sometimes easy to diagnose: a case report and review of the literature
World Journal of Emergency Surgery, 11/16/09    Relevance Score: 66%

Components of the metabolic syndrome in 500 adult long-term survivors of childhood cancer
Annals of Oncology, 10/29/09    Relevance Score: 66%

The Metabolic Syndrome: A Modern Plague Spread by Modern Technology
The Journal of Clinical Hypertension, 10/06/09    Relevance Score: 66%

Today in Neuro/Psych pharmacology...keeping you current

Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy
Journal of Neuro-Oncology, 12/04/09

Combination therapy of 17(beta)-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke
Journal of Pharmacology and Experimental Therapeutics, 12/04/09

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: Too little juice or a miswired brain
Molecular Pharmacology, 12/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address